RS59670B1 - Himerni polipeptidi faktora viii i njihove upotrebe - Google Patents
Himerni polipeptidi faktora viii i njihove upotrebeInfo
- Publication number
- RS59670B1 RS59670B1 RS20191424A RSP20191424A RS59670B1 RS 59670 B1 RS59670 B1 RS 59670B1 RS 20191424 A RS20191424 A RS 20191424A RS P20191424 A RSP20191424 A RS P20191424A RS 59670 B1 RS59670 B1 RS 59670B1
- Authority
- RS
- Serbia
- Prior art keywords
- factor viii
- chimeric factor
- viii polypeptides
- polypeptides
- chimeric
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261586099P | 2012-01-12 | 2012-01-12 | |
| US201261586654P | 2012-01-13 | 2012-01-13 | |
| US201261667901P | 2012-07-03 | 2012-07-03 | |
| US201261734954P | 2012-12-07 | 2012-12-07 | |
| EP13735649.9A EP2804623B1 (en) | 2012-01-12 | 2013-01-12 | Chimeric factor viii polypeptides and uses thereof |
| PCT/US2013/021330 WO2013106787A1 (en) | 2012-01-12 | 2013-01-12 | Chimeric factor viii polypeptides and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS59670B1 true RS59670B1 (sr) | 2020-01-31 |
Family
ID=48781968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20191424A RS59670B1 (sr) | 2012-01-12 | 2013-01-12 | Himerni polipeptidi faktora viii i njihove upotrebe |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US11370827B2 (sr) |
| EP (2) | EP2804623B1 (sr) |
| JP (4) | JP6255630B2 (sr) |
| KR (1) | KR102212098B1 (sr) |
| CN (4) | CN104271150A (sr) |
| AU (2) | AU2016202875B2 (sr) |
| BR (1) | BR112014017165B1 (sr) |
| CA (1) | CA2863328A1 (sr) |
| CO (1) | CO7010788A2 (sr) |
| CY (1) | CY1122509T1 (sr) |
| DK (1) | DK2804623T3 (sr) |
| EA (2) | EA035323B1 (sr) |
| ES (1) | ES2753124T3 (sr) |
| HK (1) | HK1202799A1 (sr) |
| HR (1) | HRP20191920T1 (sr) |
| HU (1) | HUE046396T2 (sr) |
| IL (2) | IL233463B (sr) |
| LT (1) | LT2804623T (sr) |
| MX (1) | MX357403B (sr) |
| MY (1) | MY201293A (sr) |
| NZ (1) | NZ626945A (sr) |
| PH (2) | PH12014501602B1 (sr) |
| PL (1) | PL2804623T3 (sr) |
| PT (1) | PT2804623T (sr) |
| RS (1) | RS59670B1 (sr) |
| SG (2) | SG10201610193RA (sr) |
| SI (1) | SI2804623T1 (sr) |
| TW (3) | TWI826778B (sr) |
| WO (1) | WO2013106787A1 (sr) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006063031A2 (en) | 2004-12-06 | 2006-06-15 | Haplomics | Allelic variants of human factor viii |
| CA2728012C (en) | 2008-06-24 | 2017-10-31 | Csl Behring Gmbh | Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life |
| AU2010290077C1 (en) | 2009-08-24 | 2015-12-03 | Bioverativ Therapeutics Inc. | Coagulation factor IX compositions and methods of making and using same |
| WO2013106787A1 (en) | 2012-01-12 | 2013-07-18 | Biogen Idec Ma Inc. | Chimeric factor viii polypeptides and uses thereof |
| RS63870B1 (sr) | 2012-02-15 | 2023-01-31 | Bioverativ Therapeutics Inc | Sastavi faktora viii i postupci za pravljenje i upotrebu istih |
| NZ628014A (en) | 2012-02-15 | 2016-09-30 | Biogen Ma Inc | Recombinant factor viii proteins |
| AU2013270682A1 (en) | 2012-06-08 | 2014-12-11 | Biogen Ma Inc. | Procoagulant compounds |
| EP2863940A4 (en) | 2012-06-08 | 2016-08-10 | Biogen Ma Inc | CHIMERIC COAGULATION FACTORS |
| US10023628B2 (en) | 2012-07-06 | 2018-07-17 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor VIII polypeptides and uses thereof |
| KR102403545B1 (ko) | 2012-07-11 | 2022-05-30 | 바이오버라티브 테라퓨틱스 인크. | Xten 및 폰 빌레브란트 인자 단백질과의 viii 인자 복합체 및 이의 용도 |
| US10272163B2 (en) | 2012-12-07 | 2019-04-30 | The Regents Of The University Of California | Factor VIII mutation repair and tolerance induction |
| ES2959747T3 (es) | 2013-02-15 | 2024-02-28 | Bioverativ Therapeutics Inc | Gen del factor VIII optimizado |
| SG11201505926VA (en) | 2013-03-15 | 2015-09-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
| ES2657291T3 (es) | 2013-04-22 | 2018-03-02 | Csl Ltd. | Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro |
| SG10201913738YA (en) * | 2013-06-28 | 2020-03-30 | Bioverativ Therapeutics Inc | Thrombin cleavable linker with xten and its uses thereof |
| US20160229903A1 (en) * | 2013-06-28 | 2016-08-11 | Biogen Ma Inc. | Thrombin cleavable linker |
| WO2015021423A2 (en) * | 2013-08-08 | 2015-02-12 | Biogen Idec Ma Inc. | Purification of chimeric fviii molecules |
| EP3033097B1 (en) | 2013-08-14 | 2021-03-10 | Bioverativ Therapeutics Inc. | Factor viii-xten fusions and uses thereof |
| HUE057005T2 (hu) | 2013-09-25 | 2022-04-28 | Bioverativ Therapeutics Inc | Oszlopon történõ vírusinaktiváló eljárások |
| CN117106095A (zh) * | 2014-01-10 | 2023-11-24 | 比奥贝拉蒂治疗公司 | 因子viii嵌合蛋白及其用途 |
| US10253088B2 (en) * | 2014-07-02 | 2019-04-09 | CSL Behring Lengnau AG | Modified von Willebrand Factor |
| US10626164B2 (en) | 2014-07-25 | 2020-04-21 | Csl Limited | Purification of VWF |
| EP3253786A4 (en) * | 2015-02-06 | 2018-10-17 | The University of North Carolina at Chapel Hill | Optimized human clotting factor viii gene expression cassettes and their use |
| ES2774011T3 (es) | 2015-05-22 | 2020-07-16 | CSL Behring Lengnau AG | Polipéptidos del factor de von Willebrand truncado para tratar la hemofilia |
| US10772936B2 (en) | 2015-05-22 | 2020-09-15 | CSL Behring Lengnau AG | Methods for preparing modified von Willebrand factor |
| TWI741992B (zh) | 2015-08-03 | 2021-10-11 | 美商百歐維拉提夫治療公司 | 因子ｉｘ融合蛋白以及其製備及使用方法 |
| US10596232B2 (en) | 2015-08-12 | 2020-03-24 | Cell Machines, Inc. | Methods and compositions related to long half-life coagulation complexes |
| BR112018008519A2 (pt) | 2015-10-28 | 2018-11-06 | Sangamo Therapeutics Inc | construtos específicos de fígado, cassetes de expressão de fator viii e métodos de uso dos mesmos |
| KR20230008256A (ko) | 2015-11-13 | 2023-01-13 | 다케다 야쿠힌 고교 가부시키가이샤 | A형 혈우병의 유전자 요법을 위한 증가된 발현을 갖는 재조합 fviii 변이체를 인코딩하는 바이러스 벡터 |
| WO2017112895A1 (en) * | 2015-12-23 | 2017-06-29 | Haplomics, Inc. | F8 gene repair |
| EP3400002B1 (en) | 2016-01-07 | 2022-02-02 | CSL Behring Lengnau AG | Mutated truncated von willebrand factor |
| HRP20221089T1 (hr) | 2016-02-01 | 2022-11-25 | Bioverativ Therapeutics Inc. | Optimizirani geni faktora viii |
| EP3417058B1 (en) * | 2016-02-16 | 2021-09-22 | Research Development Foundation | Sortase-modified molecules and uses thereof |
| JP2019522962A (ja) * | 2016-05-20 | 2019-08-22 | オクタファルマ アクチェン ゲゼルシャフト | 改善された薬物動態を有する、グリコシル化ｖｗｆ融合タンパク質 |
| US11046749B2 (en) | 2016-06-24 | 2021-06-29 | Mogam Institute For Biomedical Research | Chimera protein comprising FVIII and vWF factors, and use thereof |
| EP3476860A4 (en) * | 2016-06-24 | 2020-01-22 | Mogam Institute for Biomedical Research | RECOMBINANT SINGLE CHAIN FVIII AND CHEMICAL CONJUGATE THEREOF |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| SG11201903950UA (en) | 2016-11-11 | 2019-05-30 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for treating hemophilia |
| TW201828974A (zh) | 2016-11-11 | 2018-08-16 | 瑞士商Ｃｓｌ貝林重組技能公司 | 用於血管外施予以治療或預防凝血疾病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類 |
| CN110520149A (zh) | 2016-12-02 | 2019-11-29 | 比奥维拉迪维治疗股份有限公司 | 诱导对凝血因子的免疫耐受性的方法 |
| EP3548066A1 (en) | 2016-12-02 | 2019-10-09 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
| CN118184797A (zh) * | 2017-02-27 | 2024-06-14 | 沙塔克实验室有限公司 | 基于vsig8的嵌合蛋白 |
| CA3068098A1 (en) | 2017-06-22 | 2018-12-27 | CSL Behring Lengnau AG | Modulation of fviii immunogenicity by truncated vwf |
| US20210163986A1 (en) | 2017-08-09 | 2021-06-03 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof |
| AU2019215063A1 (en) | 2018-02-01 | 2020-09-03 | Bioverativ Therapeutics, Inc. | Use of lentiviral vectors expressing Factor VIII |
| WO2019219049A1 (zh) * | 2018-05-18 | 2019-11-21 | 北京辅仁瑞辉生物医药研究院有限公司 | 改进的fviii融合蛋白及其应用 |
| CN113166271A (zh) * | 2018-05-18 | 2021-07-23 | 郑州晟斯生物科技有限公司 | 具有延长半衰期的融合多肽缀合物 |
| JP2021523878A (ja) | 2018-05-18 | 2021-09-09 | バイオベラティブ セラピューティクス インコーポレイテッド | 血友病ａを処置する方法 |
| US20220073637A1 (en) * | 2018-06-29 | 2022-03-10 | City Of Hope | Compositions and methods for treating autoimmune diseases |
| CA3106590A1 (en) | 2018-07-16 | 2020-01-23 | Baxalta Incorporated | Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression |
| US20200069817A1 (en) | 2018-08-09 | 2020-03-05 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| CA3127065A1 (en) | 2019-01-16 | 2020-07-23 | Baxalta Incorporated | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
| US10654911B1 (en) * | 2019-04-02 | 2020-05-19 | Beijing Neoletix Biological Technology Co., Ltd. | Vector co-expressing truncated von Willebrand factor and factor VIII |
| EP3736286A1 (en) | 2019-05-09 | 2020-11-11 | Biotest AG | Single chain factor viii molecule |
| CN112175088B (zh) * | 2019-07-02 | 2023-03-28 | 江苏晟斯生物制药有限公司 | 改进的fix融合蛋白、缀合物及其应用 |
| KR20220029733A (ko) | 2019-07-04 | 2022-03-08 | 체에스엘 베링 렝나우 아게 | 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf) |
| JP2022546525A (ja) * | 2019-09-02 | 2022-11-04 | ビオテスト・アクチエンゲゼルシャフト | 延長された半減期を有する第ｖｉｉｉ因子タンパク質 |
| EP3785726A1 (en) * | 2019-09-02 | 2021-03-03 | Biotest AG | Factor viii protein with increased half-life |
| WO2021067389A1 (en) | 2019-09-30 | 2021-04-08 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
| JP2023500953A (ja) | 2019-11-11 | 2023-01-11 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 第ｖｉｉｉ因子に対する寛容を誘導するためのポリペプチド |
| EP4073098B1 (en) * | 2019-12-19 | 2023-09-27 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
| CN113087803B (zh) * | 2021-05-12 | 2022-10-14 | 苏州大学附属第一医院 | 抗人血管性血友病因子前导肽单克隆抗体sz176及其应用 |
| WO2023159135A2 (en) * | 2022-02-16 | 2023-08-24 | University Of Miami | Il-2 and tl1a fusion proteins and methods of use thereof |
Family Cites Families (159)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| CA1341174C (en) | 1985-04-12 | 2001-01-30 | John J. Toole Jr. | Procoagulant proteins derived from factor viii: c |
| KR910006424B1 (ko) | 1985-08-21 | 1991-08-24 | 인코텍스 비.브이 | 편성브리프(brief) 제조방법 |
| DE3785102T2 (de) | 1986-01-03 | 1993-07-22 | Genetics Inst | Verfahren zur herstellung von faktor-viii:c-typ-proteinen. |
| US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US5422260A (en) * | 1986-05-29 | 1995-06-06 | Genetics Institute, Inc. -Legal Affairs | Human factor VIII:c muteins |
| US5543502A (en) | 1986-06-24 | 1996-08-06 | Novo Nordisk A/S | Process for producing a coagulation active complex of factor VIII fragments |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| CA1331157C (en) | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
| US6060447A (en) | 1987-05-19 | 2000-05-09 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
| US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
| IE69026B1 (en) | 1987-06-12 | 1996-08-07 | Immuno Ag | Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
| DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
| FR2619314B1 (fr) | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
| US4994371A (en) | 1987-08-28 | 1991-02-19 | Davie Earl W | DNA preparation of Christmas factor and use of DNA sequences |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| US5004803A (en) | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
| SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
| US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
| US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
| US6376463B1 (en) | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
| US6037452A (en) | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
| US5563045A (en) | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
| US6818439B1 (en) | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
| AU3968897A (en) | 1996-08-02 | 1998-02-25 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US20020019036A1 (en) * | 1996-12-13 | 2002-02-14 | Hans-Peter Schwarz | Von willebrand factor derivatives and methods of isolating proteins that bind to von willebrand factor |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| DK1068241T3 (da) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antistofvarianter og fragmenter deraf |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| JP2002522063A (ja) | 1998-08-17 | 2002-07-23 | アブジェニックス インコーポレイテッド | 増加した血清半減期を有する改変された分子の生成 |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| US6358703B1 (en) | 1998-12-10 | 2002-03-19 | Bayer Corporation | Expression system for factor VIII |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR101155191B1 (ko) | 1999-01-15 | 2012-06-13 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US7829085B2 (en) * | 1999-07-14 | 2010-11-09 | Life Sciences Research Partners Vzw | Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII |
| CA2405557C (en) | 2000-04-12 | 2013-09-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| ES2256234T3 (es) | 2000-05-16 | 2006-07-16 | Lipoxen Technologies Limited | Derivatizacion de proteinas en solucion acuosa. |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| DE60143544D1 (de) | 2000-12-12 | 2011-01-05 | Medimmune Llc | Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| CA2450125A1 (en) * | 2001-06-15 | 2002-12-27 | Andre C. Schuh | Gene therapy for hemophilia a |
| US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| KR101271635B1 (ko) | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| EP2261250B1 (en) | 2001-12-21 | 2015-07-01 | Human Genome Sciences, Inc. | GCSF-Albumin fusion proteins |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| KR20040088572A (ko) | 2002-03-01 | 2004-10-16 | 이뮤노메딕스, 인코오포레이티드 | 제거율 증강을 위한 양특이성 항체 점 돌연변이들 |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| EP1487992A4 (en) | 2002-03-15 | 2007-10-31 | Brigham & Womens Hospital | CENTRAL AIRWAY DELIVERY FOR SYSTEMIC DRUG DELIVERY |
| US7425620B2 (en) | 2002-08-14 | 2008-09-16 | Scott Koenig | FcγRIIB-specific antibodies and methods of use thereof |
| WO2004027901A2 (en) | 2002-09-17 | 2004-04-01 | Diffusion Science, Inc. | Electrochemical generation, storage and reaction of hydrogen and oxygen using gas permeable catalyst-coated hollow microspheres |
| EP2364996B1 (en) | 2002-09-27 | 2016-11-09 | Xencor Inc. | Optimized FC variants and methods for their generation |
| SI1562972T1 (sl) | 2002-10-15 | 2010-12-31 | Facet Biotech Corp | ALTERACIJA FcRn VEZANIH AFINITET ALI SERUMSKIH RAZPOLOVNIH DOB ANTITELESC Z MUTAGENEZO |
| GB2395337B (en) | 2002-11-14 | 2005-12-28 | Gary Michael Wilson | Warning Unit |
| ES2897506T3 (es) | 2003-01-09 | 2022-03-01 | Macrogenics Inc | Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos |
| US7041635B2 (en) * | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| CN102139114A (zh) | 2003-02-26 | 2011-08-03 | 尼克塔治疗公司 | 聚合物-因子viii部分缀合物 |
| WO2004076522A1 (ja) | 2003-02-28 | 2004-09-10 | Kuraray Co., Ltd. | 硬化性樹脂組成物 |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| ATE497783T1 (de) | 2003-05-06 | 2011-02-15 | Syntonix Pharmaceuticals Inc | Gerinnungsfaktor vii-fc chimäre proteine zur behandlung von hämostatischen krankheiten |
| EP1654290B1 (en) | 2003-08-12 | 2019-03-13 | Lipoxen Technologies Limited | Sialic acid derivatives for protein derivatisation and conjugation |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| WO2005077981A2 (en) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
| WO2005070963A1 (en) | 2004-01-12 | 2005-08-04 | Applied Molecular Evolution, Inc | Fc region variants |
| US7276585B2 (en) | 2004-03-24 | 2007-10-02 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
| SI2471813T1 (sl) | 2004-07-15 | 2015-03-31 | Xencor, Inc. | Optimirane Fc variante |
| US7566701B2 (en) | 2004-09-07 | 2009-07-28 | Archemix Corp. | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| EP1835938B1 (en) * | 2004-12-27 | 2013-08-07 | Baxter International Inc. | Polymer-von willebrand factor-conjugates |
| EP1924596A4 (en) | 2005-08-12 | 2009-07-29 | Human Genome Sciences Inc | ALBUM INFUSION PROTEINS |
| US7855279B2 (en) * | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| US7846445B2 (en) | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
| EP1996937A4 (en) * | 2006-03-06 | 2009-04-08 | Amunix Inc | GENETIC PACKS AND USES THEREOF |
| CN101415445A (zh) * | 2006-03-31 | 2009-04-22 | 巴克斯特国际公司 | 聚乙二醇化的因子ⅷ |
| WO2007144173A1 (en) | 2006-06-14 | 2007-12-21 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
| EP1867660A1 (en) | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
| US20080242607A1 (en) * | 2006-07-21 | 2008-10-02 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
| EP2068905A4 (en) | 2006-09-14 | 2009-12-30 | Human Genome Sciences Inc | ALBUM INFUSION PROTEINS |
| US20100075375A1 (en) * | 2006-10-03 | 2010-03-25 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
| JP5457185B2 (ja) | 2006-10-04 | 2014-04-02 | ノヴォ ノルディスク アー／エス | グリセロール連結のｐｅｇ化された糖および糖ペプチド |
| CA2673459C (en) | 2006-12-22 | 2016-09-13 | Stefan Schulte | Modified coagulation factors with prolonged in vivo half-life |
| EP1935430A1 (en) * | 2006-12-22 | 2008-06-25 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
| WO2008127702A2 (en) * | 2007-04-13 | 2008-10-23 | Catalyst Biosciences, Inc. | Modified factor vii polypetides and uses thereof |
| WO2008151258A2 (en) | 2007-06-04 | 2008-12-11 | Neose Technologies, Inc. | O-linked glycosylation using n-acetylglucosaminyl transferases |
| DK2369005T3 (da) | 2007-06-21 | 2013-06-24 | Univ Muenchen Tech | Biologisk aktive proteiner med forøget stabilitet in vivo og/eller in vitro |
| AU2008287340A1 (en) * | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| CA2703948A1 (en) | 2007-11-01 | 2009-05-07 | University Of Rochester | Recombinant factor viii having increased stability |
| US8173597B2 (en) | 2007-11-09 | 2012-05-08 | Baxter International Inc. | Modified recombinant factor VIII and von Willebrand factor and methods of use |
| EP3936116A1 (en) | 2007-12-28 | 2022-01-12 | Takeda Pharmaceutical Company Limited | Rrecombinant vwf containing formulations |
| ES2298096B1 (es) * | 2008-01-08 | 2009-01-01 | Grifols, S.A. | Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos. |
| CA2728012C (en) * | 2008-06-24 | 2017-10-31 | Csl Behring Gmbh | Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life |
| DE102008032361A1 (de) * | 2008-07-10 | 2010-01-21 | Csl Behring Gmbh | Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie |
| CA3092223C (en) * | 2008-07-21 | 2023-01-03 | Apogenix Ag | Tnfsf single chain molecules |
| EP2368124A4 (en) | 2008-11-24 | 2012-09-19 | Bayer Healthcare Llc | METHOD FOR DETERMINING THE ACTIVITY OF A PEGYLATED BLOOD GENERATION FACTOR IN A SILICON-BASED ACTIVATED PART THROMBOPLASTINE TIME ASSAY |
| CN102348715B (zh) * | 2009-02-03 | 2017-12-08 | 阿穆尼克斯运营公司 | 延伸重组多肽和包含该延伸重组多肽的组合物 |
| US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
| US20120142593A1 (en) * | 2009-03-24 | 2012-06-07 | Bayer Healthcare Llc | Factor VIII Variants and Methods of Use |
| DE202010018378U1 (de) | 2009-04-10 | 2016-04-07 | Tufts Medical Center, Inc. | PAR-1-Aktivierung durch Metalloproteinase-1 (MMP-1) |
| NZ596778A (en) | 2009-06-08 | 2013-11-29 | Amunix Operating Inc | Glucose-regulating polypeptides and methods of making and using same |
| CN106916229A (zh) | 2009-06-08 | 2017-07-04 | 阿穆尼克斯运营公司 | 生长激素多肽及其制备和使用方法 |
| AU2010284977A1 (en) * | 2009-08-20 | 2012-03-29 | Csl Behring Gmbh | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
| AU2010290077C1 (en) | 2009-08-24 | 2015-12-03 | Bioverativ Therapeutics Inc. | Coagulation factor IX compositions and methods of making and using same |
| WO2011028344A2 (en) | 2009-08-25 | 2011-03-10 | Amunix Operating Inc. | Interleukin-1 receptor antagonist compositions and methods of making and using same |
| PL2499165T3 (pl) | 2009-11-13 | 2017-04-28 | Grifols Therapeutics Inc. | Preparaty zawierające czynnik von willenbranda (vwf) oraz sposoby, zestawy i zastosowania z nim powiązane |
| AU2010325787B2 (en) | 2009-12-06 | 2016-05-12 | Bioverativ Therapeutics Inc. | Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof |
| EP2977055A1 (en) * | 2010-02-16 | 2016-01-27 | Novo Nordisk A/S | Factor viii fusion protein |
| CN102770449B (zh) | 2010-02-16 | 2016-02-24 | 诺沃—诺迪斯克有限公司 | 具有降低的vwf结合的因子viii分子 |
| WO2011123830A2 (en) | 2010-04-02 | 2011-10-06 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
| ES2813650T3 (es) | 2010-05-20 | 2021-03-24 | Allergan Inc | Toxinas clostridiales degradables |
| EP3508573A1 (en) | 2010-07-09 | 2019-07-10 | Bioverativ Therapeutics Inc. | Systems for factor viii processing and methods thereof |
| NZ605400A (en) | 2010-07-09 | 2015-05-29 | Biogen Idec Hemophilia Inc | Chimeric clotting factors |
| US20130017997A1 (en) | 2010-08-19 | 2013-01-17 | Amunix Operating Inc. | Factor VIII Compositions and Methods of Making and Using Same |
| WO2013106787A1 (en) | 2012-01-12 | 2013-07-18 | Biogen Idec Ma Inc. | Chimeric factor viii polypeptides and uses thereof |
| RS63870B1 (sr) | 2012-02-15 | 2023-01-31 | Bioverativ Therapeutics Inc | Sastavi faktora viii i postupci za pravljenje i upotrebu istih |
| NZ628014A (en) | 2012-02-15 | 2016-09-30 | Biogen Ma Inc | Recombinant factor viii proteins |
| KR102403545B1 (ko) | 2012-07-11 | 2022-05-30 | 바이오버라티브 테라퓨틱스 인크. | Xten 및 폰 빌레브란트 인자 단백질과의 viii 인자 복합체 및 이의 용도 |
| SG10201913738YA (en) | 2013-06-28 | 2020-03-30 | Bioverativ Therapeutics Inc | Thrombin cleavable linker with xten and its uses thereof |
| US20160229903A1 (en) | 2013-06-28 | 2016-08-11 | Biogen Ma Inc. | Thrombin cleavable linker |
| CN117106095A (zh) | 2014-01-10 | 2023-11-24 | 比奥贝拉蒂治疗公司 | 因子viii嵌合蛋白及其用途 |
-
2013
- 2013-01-12 WO PCT/US2013/021330 patent/WO2013106787A1/en active Application Filing
- 2013-01-12 BR BR112014017165-3A patent/BR112014017165B1/pt active IP Right Grant
- 2013-01-12 EP EP13735649.9A patent/EP2804623B1/en active Active
- 2013-01-12 EP EP18211179.9A patent/EP3505179A1/en active Pending
- 2013-01-12 CN CN201380013452.7A patent/CN104271150A/zh active Pending
- 2013-01-12 PL PL13735649T patent/PL2804623T3/pl unknown
- 2013-01-12 RS RS20191424A patent/RS59670B1/sr unknown
- 2013-01-12 SG SG10201610193RA patent/SG10201610193RA/en unknown
- 2013-01-12 PT PT137356499T patent/PT2804623T/pt unknown
- 2013-01-12 EA EA201791134A patent/EA035323B1/ru unknown
- 2013-01-12 DK DK13735649T patent/DK2804623T3/da active
- 2013-01-12 MY MYPI2018001814A patent/MY201293A/en unknown
- 2013-01-12 ES ES13735649T patent/ES2753124T3/es active Active
- 2013-01-12 LT LT13735649T patent/LT2804623T/lt unknown
- 2013-01-12 CA CA2863328A patent/CA2863328A1/en active Pending
- 2013-01-12 KR KR1020147022369A patent/KR102212098B1/ko active IP Right Grant
- 2013-01-12 HU HUE13735649A patent/HUE046396T2/hu unknown
- 2013-01-12 JP JP2014552353A patent/JP6255630B2/ja active Active
- 2013-01-12 CN CN201810666645.7A patent/CN109111526A/zh active Pending
- 2013-01-12 EA EA201491186A patent/EA028309B1/ru not_active IP Right Cessation
- 2013-01-12 SG SG11201403764XA patent/SG11201403764XA/en unknown
- 2013-01-12 US US14/371,948 patent/US11370827B2/en active Active
- 2013-01-12 SI SI201331602T patent/SI2804623T1/sl unknown
- 2013-01-12 CN CN201911267518.0A patent/CN111499761A/zh active Pending
- 2013-01-12 NZ NZ626945A patent/NZ626945A/en unknown
- 2013-01-12 CN CN201911266598.8A patent/CN111499760A/zh active Pending
- 2013-01-12 MX MX2014008512A patent/MX357403B/es active IP Right Grant
- 2013-01-14 TW TW110112317A patent/TWI826778B/zh active
- 2013-01-14 TW TW102101337A patent/TW201348253A/zh unknown
- 2013-01-14 TW TW107124686A patent/TWI727187B/zh active
-
2014
- 2014-06-30 IL IL233463A patent/IL233463B/en active IP Right Grant
- 2014-07-11 PH PH12014501602A patent/PH12014501602B1/en unknown
- 2014-07-15 CO CO14152717A patent/CO7010788A2/es unknown
-
2015
- 2015-04-01 HK HK15103334.2A patent/HK1202799A1/xx unknown
-
2016
- 2016-05-04 AU AU2016202875A patent/AU2016202875B2/en active Active
-
2017
- 2017-11-15 JP JP2017219879A patent/JP6728121B2/ja active Active
-
2018
- 2018-02-16 AU AU2018201163A patent/AU2018201163B2/en active Active
- 2018-06-13 PH PH12018501250A patent/PH12018501250A1/en unknown
- 2018-09-05 IL IL261632A patent/IL261632B/en unknown
-
2019
- 2019-10-22 HR HRP20191920TT patent/HRP20191920T1/hr unknown
- 2019-11-07 CY CY20191101171T patent/CY1122509T1/el unknown
-
2020
- 2020-02-26 JP JP2020030737A patent/JP7113860B2/ja active Active
-
2022
- 2022-05-27 US US17/826,932 patent/US20230011438A1/en active Pending
- 2022-07-26 JP JP2022118552A patent/JP7475613B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL261632B (en) | Chimeric factor viii polypeptides and uses thereof | |
| IL291571A (en) | cx3cr1 binding polypeptides | |
| HK1217731A1 (zh) | 異源二聚化多肽 | |
| HK1210790A1 (en) | Modified factor polypeptides and uses thereof | |
| EP2870170A4 (en) | NOVEL PEPTIDES AND THEIR USE | |
| EP2929045A4 (en) | PROTEIN EXPRESSION REINFORCING POLYPEPTIDES | |
| GB201220474D0 (en) | Polypeptides | |
| GB201201100D0 (en) | Polypeptides and methods | |
| SG11201500111VA (en) | Peptides and uses thereof | |
| SG11201501646PA (en) | Peptides and their uses | |
| HK1205747A1 (en) | Modified adiponectin polypeptides and their uses | |
| EP2825548A4 (en) | MODIFIED KISSPEPTIN PEPTIDES AND USES THEREOF | |
| HK1211042A1 (en) | Inflammation-enabling polypeptides and uses thereof | |
| HK1201050A1 (en) | Polypeptides and their use | |
| SG11201402139UA (en) | High mast2-affinity polypeptides and uses thereof | |
| ZA201504462B (en) | TGFß-DERIVED POLYPEPTIDES AND USES THEREOF | |
| EP2918600A4 (en) | NEW PEPTIDE AND ITS USE | |
| GB201210303D0 (en) | Polypeptides and methods | |
| GB201214769D0 (en) | Methodsa and peptides |